Mitoxantrone is a Topoisomerase II Inhibitor for Leukemia Research
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia, which defined as a minimum of 5 × 109/L monoclonal B cells in the blood. However, CLL affects approximately…
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia, which defined as a minimum of 5 × 109/L monoclonal B cells in the blood. However, CLL affects approximately…
Topoisomerases are enzymes that regulate the overwinding or underwinding of DNA. The double stranded nature of DNA creates a special set of problems for processes that require strand unwinding such…
Acute myeloid leukemia (AML) is a group of malignant diseases of the hematopoietic system. And, AML occurs as the result of mutations in hematopoietic stem/progenitor cells. Despite advances in treatment,…
Bcl-2 family proteins, known as B-cell lymphoma 2, are regulators of programmed cell death. Additionally, the bcl-2 family includes pro-apoptotic and anti-apoptotic proteins. Anti-apoptotic proteins refer to Bcl-2, Bcl-x (L),…
Melanoma is a type of skin cancer that is caused by a malignant proliferation of melanocytes. Ultraviolet light (UV) exposure can change DNA and its expressions and is the primary…
MDM2 and MDM4 have established cancer drug targets. Additionally, they are also inhibitors of p53 activity and are amplified in many cancer types. In particular, the targeting of MDM2–p53 interactions…
Cytostatic agents are cell components or drugs that inhibit cell division. Specifically, cell growth arrest is an important prerequisite for structured multicellular organisms. Cell inhibitors achieve these growth-inhibitory effects through…
On December 1, 2022, FDA approved Rezlidhea (Olutasidenib) to treat adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible (IDH1) mutation. Olutasidenib (FT2102) is a highly potent,…
BTK, Bruton’s tyrosine kinase, belongs to the cytoplasmatic kinases TEC subfamily. BTK involves in immune regulation, and is activated by Src kinases. Then BTK leads to phospholipase-Cγ (PLCγ) phosphorylation, Ca2+…
Purinostat mesylate is a selective inhibitor of HDAC. This compound inhibits class I and class IIb HDACs with IC50s from 0.81 to 11.5 nM. Purinostat mesylate (1-10 μM) inhibits HDAC1, 2, 3,…